Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
130
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Takashi Oyamaa Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Kensuke Matsudaa Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Akira Hondaa Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Megumi Yasunagaa Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Kumi Nakazakia Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Hiroaki Makia Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Yosuke Masamotoa Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
&
Mineo Kurokawaa Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;b Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, JapanCorrespondence[email protected]
 show all
Pages 3497-3500 | Received 01 Jul 2022, Accepted 25 Sep 2022, Published online: 12 Oct 2022

References

  • Montesinos P, Díaz-Mediavilla J, Debén G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009;94(9):1242–1249.
  • de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006;20(1):35–41.
  • Furuya A, Kawahara M, Kumode M, et al. Central nervous system involvement of acute promyelocytic leukemia, three case reports. Clin Case Rep. 2017;5(5):645–653.
  • Au WY, Tam S, Fong BM, et al. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008;112(9):3587–3590.
  • Nagai S, Nannya Y, Arai S, et al. Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Haematologica. 2010;95(1):169–171.
  • Vega-Ruiz A, Faderl S, Estrov Z, et al. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009;89(4):489–496.
  • Sahin DG, Gunduz E, Akay OM, et al. Central nervous system relapse in a patient with acute promyelocytic leukaemia: does the risk stratification matter? BMJ Case Rep. 2013;2013(1):bcr2013009456.
  • Colovic N, Tomin D, Vidovic A, et al. Central nervous system relapse in CD56+, FLT3/ITD + promyelocytic leukemia. Med Oncol. 2012;29(1):260–262.
  • Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11(6):123.
  • Fouzia NA, Sharma V, Ganesan S, et al. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Br J Haematol. 2021;192(2):292–299.
  • Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20(1):57–65.
  • Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
  • Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
  • Gleissner B, Siehl J, Korfel A, et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58(3):390–396.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.